To further explore the potential role of these molecules in tumor lymphangiogenesis, we next quantitated LYVE-1, VEGF-C and VEGF-D transcripts in the same tumor series finding that, as expected, expression of these genes was higher in the more aggressive ER− breast tumors (Figure 6B). This evidence concerns the gene VEGFC and neoplasm.